Science Explorer Interactive view Map
Company · Beverly · United States

CytoCure (United States)

Research works
13
▼ 68% vs 2013–17
Citations
261
20.7 per fractional work
Top-10% rate
20.0%
record average 16.5%
Open access
45%
world 28%

Not ranked overall: CytoCure (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which research topics does CytoCure (United States) publish most on?

By volume in 2022–2025: CAR-T cell therapy research, T-cell and B-cell Immunology, Advanced Biosensing Techniques and Applications and Monoclonal and Polyclonal Antibodies Research.

  1. 1 CAR-T cell therapy research Oncology 1 works
  2. 2 T-cell and B-cell Immunology Immunology 1 works
  3. 3 Advanced Biosensing Techniques and Applications Molecular Biology 1 works
  4. 4 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
  5. 5 Immunodeficiency and Autoimmune Disorders Immunology 0 works
  6. 6 Cancer Immunotherapy and Biomarkers Oncology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available45.3%not open54.7%

World: 28% of research is openly available.

with international co-authors44.5%domestic only55.5%

World: 19% is written across borders.

How has CytoCure (United States)'s research output changed?

Output in 2018–2022 was 68% lower than in 2013–2017.

20102015
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Beverly

All research institutions in Beverly

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.